One Case of Abnormal Decrease of Interferon Gamma Release Assay Result Caused by Melphalan.

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2024-09-01 DOI:10.7754/Clin.Lab.2024.240437

Gangfeng Li, Tao Lu, Ningping Shan

{"title":"One Case of Abnormal Decrease of Interferon Gamma Release Assay Result Caused by Melphalan.","authors":"Gangfeng Li, Tao Lu, Ningping Shan","doi":"10.7754/Clin.Lab.2024.240437","DOIUrl":null,"url":null,"abstract":"Background: Interferon gamma release assay (IGRA) is an important method to detect the specific antigen of tuberculosis, which is crucial to the diagnosis of tuberculosis or potential tuberculosis infection.Methods: We report a case of myelosuppression caused by the use of Melphalan in the treatment of multiple myeloma, resulting in an abnormal decrease in interferon gamma release assay results.Results: We collected blood samples from the patient for retesting and the result of the test did not differ significantly. Upon reviewing the case, it was found that the patient's use of Melphalan treatment resulted in bone marrow suppression and extreme reduction of peripheral blood lymphocytes. Therefore, it is speculated that the abnormal decrease of the interferon gamma release assay result is caused by bone marrow suppression, which is caused by the use of Melphalan.Conclusions: When patients with multiple myeloma are treated with Melphalan, it can lead to bone marrow suppression and result in false negative interference gamma release assay results. Laboratory staff should consider the existence of such interference and communicate with clinical doctors in a timely manner.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"70 9","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.240437","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Interferon gamma release assay (IGRA) is an important method to detect the specific antigen of tuberculosis, which is crucial to the diagnosis of tuberculosis or potential tuberculosis infection.

Methods: We report a case of myelosuppression caused by the use of Melphalan in the treatment of multiple myeloma, resulting in an abnormal decrease in interferon gamma release assay results.

Results: We collected blood samples from the patient for retesting and the result of the test did not differ significantly. Upon reviewing the case, it was found that the patient's use of Melphalan treatment resulted in bone marrow suppression and extreme reduction of peripheral blood lymphocytes. Therefore, it is speculated that the abnormal decrease of the interferon gamma release assay result is caused by bone marrow suppression, which is caused by the use of Melphalan.

Conclusions: When patients with multiple myeloma are treated with Melphalan, it can lead to bone marrow suppression and result in false negative interference gamma release assay results. Laboratory staff should consider the existence of such interference and communicate with clinical doctors in a timely manner.

查看原文本刊更多论文

美法仑导致干扰素γ释放测定结果异常下降的一个案例

背景：干扰素γ释放测定（IGRA）是检测结核病特异性抗原的重要方法：干扰素γ释放测定（IGRA）是检测结核病特异性抗原的重要方法，对结核病或潜在结核感染的诊断至关重要：我们报告了一例因使用美法仑治疗多发性骨髓瘤而引起骨髓抑制，导致干扰素γ释放测定结果异常下降的病例：我们采集了患者的血液样本进行复检，检测结果没有明显差异。复查后发现，患者使用美法仑治疗导致骨髓抑制，外周血淋巴细胞极度减少。因此，推测干扰素γ释放测定结果的异常下降是由骨髓抑制引起的，而骨髓抑制是由使用美法仑引起的：结论：当多发性骨髓瘤患者接受美法仑治疗时，可能会导致骨髓抑制，从而导致干扰素γ释放测定结果出现假阴性。实验室工作人员应考虑到这种干扰的存在，并及时与临床医生沟通。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.